Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation
Merck (MRK) will acquire Silence Therapeutics (SLN) for $1.3B, or $20 per ADS, an 82% premium. Silence's Phase 3-ready siRNA therapy for polycythemia vera will join Merck's pipeline. The deal, expected to close in Q1 2027, aims to boost Merck's rare disease portfolio and aligns with its specialty healthcare strategy.
How this was made
The 30-second read
Why it matters
The deal expands Merck's pipeline with a Phase‑2‑ready therapy, Divesiran, targeting polycythemia vera, and signals continued investment in RNA‑based medicines.
Market read
A major pharma acquisition that could reshape the rare‑disease market and affect biotech peer valuations.
What to watch
Regulatory approval risk for Divesiran and integration challenges may temper upside.
Background
Merck seeks to bolster its rare‑disease portfolio through the acquisition of Silence Therapeutics, a UK‑based siRNA developer.
Ticker impact
Merck announced a definitive agreement to acquire Silence Therapeutics for $1.3 billion, expanding its rare‑disease pipeline.
likely modest upward pressure as investors price in pipeline expansion
Large‑scale M&A with strategic fit; market typically rewards growth acquisitions in biotech.
Silence Therapeutics is the target of Merck's $1.3 billion cash acquisition, with a 82% premium to its recent share price.
strong upward pressure toward the $20 per ADS offer
Acquisition premium and cash consideration provide a clear catalyst for a price increase.
Market effects
Strengthens the biotech/rare‑disease sector, potentially boosting peer valuations.
Highlights continued M&A activity in US‑based pharma with UK biotech targets.
Adds to the wave of large pharma acquisitions, signaling confidence in siRNA therapeutics worldwide.
Counterpoint
Merck's cash outlay could strain balance sheet and dilute earnings, weighing on the stock.
Key entities
- CompanyMerck
US‑listed pharmaceutical giant (ticker MRK) acquiring Silence Therapeutics.
- CompanySilence Therapeutics
UK‑based biotech (ticker SLN) developing siRNA therapies.
